Cara Corp (TVRD): PEG Multiple

Corporate company logo of Cara Corp (TVRD)

Revenue dynamics for Cara Therapeutics Inc (TVRD) are declining due to a liquidity shortage and reduced R&D spending. The weighted P/E relative to earnings growth rates demonstrates that the current level is around 0.00. Stability is provided by the release of pruritus treatments for kidney disease, while development is based on compliance with bioethical standards and environmental control of laboratories.

Cara Corp (TVRD): PEG Multiple from 07/04/2022 to 11/17/2026

Analytical breakdowns for Cara Corp (TVRD)

- share price and consensus valuation forecast:
- stock exchange capitalization data:
Summary company analytics:TVRD - Cara Pharma
Manufactured products of Cara Pharma

Investing in Cara Therapeutics Inc (TVRD) requires a precise valuation of growth via the PEG ratio, which clearly demonstrates the relationship between the P/E multiple and earnings growth rates. A value below one signals undervaluation; however, the slow commercialization of the lead drug and the failure of several clinical trials leave the issuer's current capital vulnerable to forecast revisions.